Tioxolone
CAS 4991-65-5
Tioxolone (CAS 4991-65-5) is a Phase 2 pharmaceutical compound with 3 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 30356.812 nM | 24 | - |
| - | IC50 | 19970.262 nM | 9 | - |
| - | EC50 | 34127.6 nM | 5 | - |
| Carbonic anhydrase 2 Enzyme |
IC50 | 5.75 | - | Homo sapiens |
| Amine oxidase [flavin-containing] B Enzyme |
IC50 | 5.02 | - | Homo sapiens |
| Amine oxidase [flavin-containing] A Enzyme |
IC50 | 5.01 | - | Homo sapiens |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Tioxolone used for in pharmaceutical contexts?
Tioxolone (CAS 4991-65-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Tioxolone?
No adverse-event association or SIDER side-effect rows are rendered for Tioxolone in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Tioxolone also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Tioxolone with EU status "permitted".
What clinical phase is Tioxolone in?
Tioxolone is rendered with ChEMBL max phase 2.
What bioactivity targets are documented for Tioxolone?
Tioxolone has 6 bioactivity rows in this page query. Rendered target entries include Carbonic anhydrase 2, Amine oxidase [flavin-containing] B, Amine oxidase [flavin-containing] A.